Promising Results with Direct‐to‐Brain Gene Therapy
American Journal of Medical Genetics Part A · 2023
DOI: 10.1002/ajmg.a.62810 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2023. Hauptthemen laut MEDLINE: Brain, Head. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
A romatic L-amino acid decarboxylase (AADC) deficiency is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine, and epinephrine (Wassenberg et al, 2017). Affected individuals can appear normal at birth, but most will begin to develop symptoms during the first months of life. The disorder most commonly leads to decreased muscle tone, or hypotonia, movement disorders including oculogyric crises, developmental delays, failure to thrive, and disruption to the autonomic nervous system. AADC deficiency is extremely rare and estimated to afflict approximately 135 children worldwide. However, its true global incidence is unknown, as there are no newborn screening programs for it. The disorder appears to be more prevalent in certain Asian populations, especially Taiwanese and Japanese, most likely due to a founder effect (Wassenberg et al, 2017). Treatment includes several medications to manage symptoms, but response among patients varies greatly, and an optimal treatment regimen can be difficult to achieve. Gene therapy has shown potential to improve the symptoms of AADC deficiency in clinical trials, and delivering the therapy directly into the brain has shown some encouraging results. Rylae-Ann Poulin, now 4 years old, was one of the first patients with AADC deficiency to benefit from gene therapy delivered in this way (Unger, 2023). Prior to treatment, by the age of 1 year, Rylae-Ann could not even lift her head. At 18 months, she entered a clinical trial that was evaluating eladocagene exuparvovec (Upstaza), a gene therapy developed by PTC Therapeutics. The single-procedure therapy comprises an adeno-associated virus vector that delivers the gene for human AADC, the dopa decarboxylase gene. “Eladocagene exuparvovec is administered through a specialized neurosurgical procedure that allows for the safe and precise delivery of the drug to the location in the brain where it is needed most: the putamen,” explains Kylie O’Keefe, Chief Commercial Officer at PTC Therapeutics. “[With the therapy] delivered to this location, patients will have the ability to produce dopamine and have it available to the parts of the brain that control the motor function.” Approved by the European Medicines Evaluation Agency and the UK for patients 18 months of age and older, eladocagene exuparvovec remains categorized as an investigational drug in the US. Its manufacturer plans to seek US regulatory approval this year. Rylae-Ann now has the motor skills and dexterity of a normal child her age, doing all the things once deemed impossible for her. According to Ms. O’Keefe, all patients in the clinical trials, independent of their age, demonstrated improvements in both motor and cognitive functional scales following treatment. “Importantly, many patients achieved developmental milestones that they were not able to perform prior to treatment,” she notes. “These milestones occurred as early as 3 months following treatment, with significant improvement continuing through 10 years of follow-up. [The treatment] also reduced symptoms that cause potentially lifethreatening and morbid complications.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
(2023). Promising Results with Direct‐to‐Brain Gene Therapy. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.62810
Vancouver
Promising Results with Direct‐to‐Brain Gene Therapy. American Journal of Medical Genetics Part A. 2023. doi:10.1002/ajmg.a.62810
BibTeX
@article{euvimed2023,
title = {Promising Results with Direct‐to‐Brain Gene Therapy},
journal = {American Journal of Medical Genetics Part A},
year = {2023},
doi = {10.1002/ajmg.a.62810}
}
EUVIMED